Company intelligence / Profile preview

Atsena Therapeutics

Durham, North Carolina, United Statesatsenatx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Atsena is advancing ATSN-201 for XLRS in Phase 1/2 LIGHTHOUSE trial with encouraging early results in Part A and has initiated Part B. ATSN-101 for LCA1 has secured a partner for global pivotal trial. Updated data from LIGHTHOUSE trial expected later in 2025.

Therapeutic areas: OphthalmologyRare Diseases
Modalities: Gene therapyAAV-based gene therapy
Industry: Biotech

Drug pipeline

9 assets

ATSN-201

8 more assets in the full pipeline.

Request access →

Partnerships

Unnamed partner for ATSN-101 global pivotal trial

Beyond the preview

Go deeper on Atsena Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atsena Therapeutics.

Explore the full profile